Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06784947 · ClinicalTrials.gov registry record · Phase 2

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

A Phase 2 study of Metastatic Colorectal Cancer (CRC) and Colorectal Cancer Stage IV, sponsored by University of Colorado, Denver.

Active
Registry status
Phase 2
Development phase
13
Enrollment target
1
Study location

NCT06784947 is a Phase 2 study of Metastatic Colorectal Cancer (CRC) and Colorectal Cancer Stage IV that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 13 participants, below the 225-participant average among 5 other Metastatic Colorectal Cancer (CRC) trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06784947, a Phase 2 study of Metastatic Colorectal Cancer (CRC) and Colorectal Cancer Stage IV, is active but no longer recruiting, sponsored by University of Colorado, Denver.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to learn if a new combination treatment is effective for patients with microsatellite stable, advanced colorectal cancer. The study treatment combines 3 drugs: atezolizumab, bevacizumab, and tiragolumab. The main questions the study aims to answer are: 1. Does the study treatment effectively treat colorectal cancer? 2. Is the study treatment safe for patients with colorectal cancer? 3. How does the study treatment effect the immune system in patients with colorectal cancer? Participants in this study will receive the study treatment and undergo checkups, laboratory tests, and imaging tests for monitoring. Some participants will also undergo tumor biopsies.

Conditions Studied

Metastatic Colorectal Cancer (CRC) Colorectal Cancer Stage IV Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Interventions

  • DRUG Bevacizumab
  • DRUG Atezolizumab
  • DRUG Tiragolumab
  • PROCEDURE Pre-Treatment Biopsy
  • PROCEDURE On-Treatment Biopsy

Study Locations (1)

Colorado

  • Universtiy of Colorado Hospital - Aurora

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2025-03-25
Est. Completion 2028-05
Phase Phase 2

Sponsor

University of Colorado, Denver

1,283 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06784947

The ClinicalTrials.gov registry entry for NCT06784947 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 225-participant average among 5 other Metastatic Colorectal Cancer (CRC) trials with a reported enrollment target (94% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Metastatic Colorectal Cancer (CRC) appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.

NCT06784947 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT06784947 about?

NCT06784947 is a clinical study titled "Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer". The goal of this study is to learn if a new combination treatment is effective for patients with microsatellite stable, advanced colorectal cancer. The study treatment combines 3 drugs: atezolizumab, bevacizumab, and tiragolumab. The main questions the study aims to answer are: 1. Does the study tr...

What is the current status of trial NCT06784947?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2025-03-25. Estimated completion is 2028-05.

What conditions does trial NCT06784947 study?

This clinical trial studies the following conditions: Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV, Microsatellite Stable (MSS) Colorectal Cancer (CRC).

What interventions are being tested in trial NCT06784947?

The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Tiragolumab (DRUG), Pre-Treatment Biopsy (PROCEDURE), On-Treatment Biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT06784947?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06784947 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Colorectal Cancer (CRC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Colorectal Cancer (CRC)

All registered trials for this condition

Colorectal Cancer Stage IV

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.